Document:

EX-4.16

 Exhibit 4.16 

SEVENTH SUPPLEMENTAL INDENTURE 

SEVENTH SUPPLEMENTAL INDENTURE (this “Seventh Supplemental Indenture”), dated as
of November 15, 2018, among Horizon Medicines LLC, a Delaware limited liability company (the “Guaranteeing Entity”) and an indirect subsidiary of Horizon Pharma USA, Inc., a Delaware corporation (the
“Company”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”). 

W I T N E S S E T H 
 WHEREAS,
Horizon Pharma Financing, Inc., a Delaware corporation (the “Escrow Issuer”) has heretofore executed and delivered to the Trustee an indenture (the “Initial Indenture”), dated as of April 29, 2015, providing
for the issuance of 6.625% Senior Notes due 2023 (the “Notes”); 
 WHEREAS, on May 7, 2015, the Escrow Issuer merged
with and into Horizon Pharma, Inc., a Delaware corporation (the “Prior Issuer”), with the Prior Issuer being the surviving entity of such merger and the Escrow Issuer ceasing to exist (the “2015 Merger”); 

WHEREAS, in connection with the 2015 Merger, the Prior Issuer, the Escrow Issuer and the Guarantors party thereto executed and delivered to
the Trustee a first supplemental indenture to the Initial Indenture (the “First Supplemental Indenture”); 
 WHEREAS, on
May 10, 2016, Horizon Pharma Rheumatology LLC executed and delivered to the Trustee a second supplemental indenture to the Initial Indenture (the “Second Supplemental Indenture”); 

WHEREAS, on October 25, 2016, Raptor Pharmaceutical Corp. and Raptor Pharmaceuticals Inc. executed and delivered to the Trustee a third
supplemental indenture to the Initial Indenture (the “Third Supplemental Indenture”); 
 WHEREAS, on October 23, 2017,
Horizon Pharma Tepro, Inc. executed and delivered to the Trustee a fourth supplemental indenture to the Initial Indenture (the “Fourth Supplemental Indenture”); 

WHEREAS, on October 19, 2018, Horizon Pharma Services LLC executed and delivered to the Trustee a fifth supplemental indenture to the
Initial Indenture (the “Fifth Supplemental Indenture”; 
 WHEREAS, on October 31, 2018, the Prior Issuer merged with
and into the Company, with the Company being the surviving entity of such merger and the Prior Issuer ceasing to exist (the “2018 Merger”); 

WHEREAS, in connection with the 2018 Merger, the Company executed and delivered to the Trustee a sixth supplemental indenture to the Initial
Indenture (the “Sixth Supplemental Indenture” and the Initial Indenture as supplemented by the First Supplemental Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture; the Fourth Supplemental Indenture, the
Fifth Supplemental Indenture and the Sixth Supplemental Indenture, the “Indenture”); 
 WHEREAS, Section 4.18 and
Section 10.03 of the Indenture provides that under certain circumstances the Guaranteeing Entity shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Entity shall unconditionally guarantee all of
the Company’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Note Guarantee”); and 

 WHEREAS, pursuant to Section 9.01(j) of the Indenture, the Trustee and the Guaranteeing
Entity are authorized to execute and deliver this Seventh Supplemental Indenture. 
 NOW, THEREFORE, in consideration of the foregoing and
for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties to this Seventh Supplemental Indenture mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to them
in the Indenture. 
 2. AGREEMENT TO GUARANTEE. The Guaranteeing Entity hereby agrees to
provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including but not limited to Article 10 thereof. 

3. NO RECOURSE AGAINST OTHERS. No director, officer, employee, incorporator or
stockholder of the Company or any Guarantor, as such, will have any liability for any obligations of the Company or the Guarantors under the Notes, this Indenture, the Note Guarantee or for any claim based on, in respect of, or by reason of, such
obligations or their creation. Each Holder of Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes. The waiver may not be effective to waive liabilities
under the federal securities laws. 
 4. NEW YORK LAW TO GOVERN; WAIVER OF JURY TRIAL. THIS SEVENTH SUPPLEMENTAL INDENTURE SHALL BE GOVERNED
BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. EACH OF THE COMPANY AND THE GUARANTORS CONSENTS AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY NEW YORK STATE OR U.S. FEDERAL COURT LOCATED IN THE BOROUGH OF MANHATTAN, CITY
OF NEW YORK, COUNTY OF NEW YORK, STATE OF NEW YORK IN RELATION TO ANY LEGAL ACTION OR PROCEEDING (I) ARISING OUT OF, RELATING TO OR IN CONNECTION WITH THIS INDENTURE, AS SUPPLEMENTED, THE NOTES, THE GUARANTEES AND ANY RELATED DOCUMENTS AND/OR
(II) ARISING UNDER ANY U.S. FEDERAL OR U.S. STATE SECURITIES LAWS IN RESPECT OF THE NOTES, THE GUARANTEES AND ANY SECURITIES ISSUED PURSUANT TO THE TERMS OF THE INDENTURE, AS SUPPLEMENTED. EACH OF THE COMPANY AND THE GUARANTORS WAIVES ANY
OBJECTION TO PROCEEDINGS IN ANY SUCH COURTS, WHETHER ON THE GROUND OF VENUE OR ON THE GROUND THAT THE PROCEEDINGS HAVE BEEN BROUGHT IN AN INCONVENIENT FORUM. EACH OF THE COMPANY AND THE GUARANTORS, TO THE EXTENT ORGANIZED OUTSIDE OF THE UNITED
STATES, SHALL APPOINT HORIZON PHARMA USA, INC. (HORIZON PHARMA USA, INC., 150 SOUTH SAUNDERS ROAD, LAKE FOREST, IL 60045), AS ITS AGENT FOR SERVICE OF PROCESS IN ANY SUCH SUIT, ACTION OR PROCEEDING AND AGREES THAT SERVICE OF PROCESS UPON SAID
AUTHORIZED AGENT SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON IT IN ANY SUCH SUIT, ACTION OR PROCEEDING. EACH OF THE COMPANY AND THE GUARANTORS AGREES TO DELIVER, UPON THE EXECUTION AND DELIVERY OF THIS SEVENTH SUPPLEMENTAL
INDENTURE, A WRITTEN ACCEPTANCE BY SUCH AGENT OF ITS APPOINTMENT AS SUCH AGENT. EACH OF THE COMPANY AND THE GUARANTORS, TO THE EXTENT ORGANIZED OUTSIDE OF THE UNITED STATES, FURTHER AGREES TO TAKE ANY AND ALL ACTION, INCLUDING THE FILING OF ANY AND
ALL SUCH DOCUMENTS AND INSTRUMENTS, AS MAY BE REASONABLY NECESSARY TO CONTINUE SUCH DESIGNATION AND APPOINTMENT OF CT CORPORATION SYSTEM IN FULL FORCE AND EFFECT FOR SO LONG AS THE INDENTURE, AS SUPPLEMENTED, REMAINS IN FORCE. THE COMPANY, THE
TRUSTEE AND EACH OF THE GUARANTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS SEVENTH SUPPLEMENTAL INDENTURE OR THE
TRANSACTIONS CONTEMPLATED HEREBY. 

 5. COUNTERPARTS. The parties may sign any number of copies of this Seventh
Supplemental Indenture. Each signed copy (which may be provided via facsimile or other electronic transmission) shall be an original, but all of them together represent the same agreement. 

6. EFFECT OF HEADINGS. The Section headings herein are for convenience only and shall not affect
the construction hereof. 
 7. THE TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for
or in respect of the validity or sufficiency of this Seventh Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Entity. 

 IN WITNESS WHEREOF, the parties hereto have caused this Seventh Supplemental Indenture to be
duly executed and attested, all as of the date first above written. 
 Dated: November 15, 2018 

 

					
	HORIZON MEDICINES LLC
		
	By:	 	 /s/ Paul W. Hoelscher

		 	Name:	 	Paul W. Hoelscher
		 	Title:	 	 Executive Vice President
 and Chief Financial
Officer

 [Signature Page to Seventh Supplemental Indenture] 

 
					
	 U.S. BANK NATIONAL ASSOCIATION,

  as Trustee

		
	By:	 	 /s/ Raymond S. Haverstock

		 	Name:	 	Raymond S. Haverstock
		 	Title:	 	Vice President

 [Signature Page to Seventh Supplemental Indenture]EX-10.3

 Exhibit 10.3 

Horizon Pharma Public Limited Company 

Non-Employee Director Compensation Policy 

Amended Effective: October 29, 2018 

Each member of the Board of Directors (the “Board”) of Horizon Pharma Public Limited Company (the “Company”)
other than (1) any member who is affiliated with any holder of more than 5% of the Company’s ordinary shares or (2) any member serving as an employee of the Company or any of its subsidiaries (each such member, a
“Director”) will receive the following compensation for his or her Board service. The determination of whether a member of the Board meets the requirements to be eligible to receive compensation as an eligible Director under
this Policy will be determined as of the date such cash compensation is otherwise payable, or the date such equity compensation would be granted, as applicable. 

Annual Cash Compensation 
 The annual cash compensation
amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If a Director joins the Board at a time other than effective as of the first day of a fiscal
quarter, each annual retainer/fee set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first
fiscal quarter in which the Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. 
  

	1.	 Annual Board Service Retainer: 

 

	 	a.	 Non-Executive Chairman of the Board/Lead Independent Director: $100,000

  

	 	b.	 All other Directors: $60,000 

 

	2.	 Annual Committee Chair Service Fee: 

 

	 	a.	 Chairman of the Audit Committee: $30,000 

 

	 	b.	 Chairman of the Compensation Committee: $20,000 

 

	 	c.	 Chairman of the Nominating & Corporate Governance Committee: $15,000 

 

	 	d.	 Chairman of the Transaction Committee: $20,000 

 

	3.	 Annual Committee Member (non-Chair) Service Fee:

  

	 	a.	 Audit Committee: $15,000 

 

	 	b.	 Compensation Committee: $10,000 

 

	 	c.	 Nominating & Corporate Governance Committee: $7,500 

 

	 	d.	 Transaction Committee: $12,500 

Equity Compensation 
 The equity compensation set forth
below will be granted under the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan, as may be amended from time to time (the “Plan”). 

  
 1. 

 1.    Initial Grant: On the date of any Director’s initial appointment or
election to the Board, the Director will be automatically, and without further action by the Board, granted restricted stock units with an aggregate value equal to $400,000, prorated based on the number days between such Director’s start date
and the first anniversary of the date of the annual shareholder meeting of the Company that most recently preceded such start date (the “Initial Grant”); provided, that if a Director’s initial election to the
Board occurs at an annual shareholder meeting of the Company, such Director will receive only the Annual Grant (as defined below) for such annual shareholder meeting and not a separate Initial Grant. The restricted stock units will vest in full upon
the first anniversary of the date of the annual shareholder meeting of the Company that most recently preceded such Director’s start date, subject to the Director’s Continuous Service (as defined in the Plan) through such vesting date. A
Director who, in the one year prior to his or her initial election to serve on the Board as a non-employee director, served as an employee of the Company or one of its subsidiaries will not be eligible for an
Initial Grant. 
 2.    Annual Grant: On the date of each annual shareholder meeting of the Company, each Director will be
automatically, and without further action by the Board, granted restricted stock units with an aggregate value of $400,000 (the “Annual Grant”). The restricted stock units will vest in full upon the first anniversary of the
date of grant, subject to the Director’s Continuous Service through such vesting date. 
 Expenses 

The Company will reimburse each Director for ordinary, necessary and reasonable
out-of-pocket travel expenses to cover in-person attendance at and participation in Board and/or Committee meetings;
provided, that Directors timely submit to the Company appropriate documentation substantiating such expenses. In addition, the Company will reimburse each Director up to $15,000 annually for financial counseling services, including
(1) personal financial planning, (2) estate planning and (3) preparation of tax returns and tax planning for the Directors and/or their dependent children. 

  
 2.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]